Ofatumumab for rheumatoid arthritis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 11, 2013, Pages

  Anand, Vidhu ^a   Garg, Sushil K ^a   Lopez Olivo, Maria Angeles ^b   Singh, Jasvinder A ^c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OFATUMUMAB;

ARTICLE; CLINICAL PROTOCOL; DATA COLLECTION METHOD; DISEASE ACTIVITY; FUNCTIONAL STATUS; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROCESS DESIGN; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

EID: 85041710008     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010833     Document Type: Article

References (56)

1. Akil M, Amos RS. ABC of rheumatology. Rheumatoid arthritis - I: Clinical features and diagnosis. BMJ 1995;310(6979):587-90.
2. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 1988;31(3):315-24.
3. Blumenauer B, Judd M, Wells G, Burls A, Cranney A, Hochberg M, et al. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD003785]
4. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis and Rheumatism 2006;54(9):2793-806.
5. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 2001;40(2):205-11.
6. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed.) 1997;315(7109):629-34. [PUBMED: 9310563]
7. Feist E, Burmester GR. Small molecules targeting JAKs - a new approach in the treatment of rheumatoid arthritis. Rheumatology 2013;52(8):1352-7.
8. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis and Rheumatism 1995;38(6):727-35.
9. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423(6937):356-61.
10. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clinical and Experimental Rheumatology 2005;23(5 Suppl 39):S93-9.
11. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis and Rheumatism 1980;23(2):137-45.
12. Health Canada. Arthritis in Canada. An ongoing challenge. Ottawa: Health Canada, 2003. [http://www.acreu.ca/pdf/Arthritis_in_Canada.pdf]
13. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
14. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
15. Jois RN, Masding A, Somerville M, Gaffney K, Scott DG. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience. Rheumatology 2007;46(6):980-2.
16. Kurrasch R, Brown JC, Chu M, Craigen J, Overend P, Patel B, et al. Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics. Journal of Rheumatology 2013;40(7):1089-96.
17. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiologica: Diagnosis 1977;18(4):481-91.
18. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358(9285):903-11.
19. Lethaby A, Lopez-Olivo MA, Maxwell L, Burls A, Tugwell P, Wells GA. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews 2013, Issue 5. [DOI: 10.1002/14651858.CD004525.pub2]
20. Liberati A, Altman DG, TetzlaffJ, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine 2009;6:e1000100.
21. Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007277.pub2]
22. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nature Reviews Immunology 2007;7(6):429-42.
23. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. New England Journal of Medicine 2011;365(23):2205-19.
24. Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD005121.pub3]
25. Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD005113.pub2]
26. National Cancer Institute. FDA Approval for Ofatumumab. 2013. Available from http://www.cancer.gov/cancertopics/druginfo/fda-ofatumumab.
27. Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD002047]
28. Ostergaard M, Baslund B, Rigby W, Rojkovich B, Jorgensen C, Dawes PT, et al. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis and Rheumatism 2010;62(8):2227-38.
29. Peschken CA, Esdaile JM. Rheumatic diseases in North America's indigenous peoples. Seminars in Arthritis and Rheumatism 1999;28(6):368-91.
30. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis and Rheumatism 1983;26(11):1346-53.
31. Prevoo ML, van Gestel AM, van T Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. British Journal of Rheumatology 1996;35(11):1101-5.
32. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2013.
33. Ruiz Garcia V, Jobanputra P, Burls A, Cabello JB, Galvez Munoz JG, Saiz Cuenca ES, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD007649.pub2]
34. Ruuls SR, Lammerts van Bueren JJ, van de Winkel JG, Parren PW. Novel human antibody therapeutics: the age of the Umabs. Biotechnology Journal 2008;3(9-10):1157-71.
35. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis and Rheumatism 2008;59(6):762-84.
36. Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis and Rheumatism 1971;14(6):706-20.
37. Shaw T, Quan J, Totoritis MC. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Annals of the Rheumatic Diseases 2003;62 Suppl 2:ii55-9.
38. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007848.pub2]
39. Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD008341]
40. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2010, Issue 7. [DOI: 10.1002/14651858.CD008331.pub2]
41. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, MacDonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD008794.pub2]
42. Spector TD. Rheumatoid arthritis. Rheumatic Diseases Clinics of North America 1990;16(3):513-37.
43. Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Methotrexate for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD000957]
44. Suarez-Almazor ME, Belseck E, Shea B, Homik J, Wells G, Tugwell P. Antimalarials for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD000959]
45. Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Sulfasalazine for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD000958]
46. Taylor PC, Quattrocchi E, Mallett S, Kurrasch R, Petersen J, Chang DJ. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Annals of the Rheumatic Diseases 2011;70(12):2119-25.
47. Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104(6):1793-800.
48. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. Journal of Immunology 2006;177(1):362-71.
49. Tugwell P, Singh JA, Wells GA. Biologicals for rheumatoid arthritis. BMJ 2011;343:d4027.
50. van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. Journal of Rheumatology 1993;20(3):579-81.
51. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. Journal of Rheumatology 1999;26(3):743-5.
52. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis and Rheumatism 1996;39(1):34-40.
53. van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nature Reviews Rheumatology 2009;5(10):531-41.
54. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. Journal of Rheumatology 1993;20(3):557-60.
55. Wong JB, Ramey DR, Singh G. Long-term morbidity, mortality, and economics of rheumatoid arthritis. Arthritis and Rheumatism 2001;44(12):2746-9.
56. Woolley DE. The mast cell in inflammatory arthritis. New England Journal of Medicine 2003;348(17):1709-11.